Summary
Mylan Inc., the nation's biggest generic drug maker, said quarterly earnings jumped 15 percent to $172 million, pushing up the stock about 14 percent in mid-morning trading.
The Canonsburg company said total revenue jumped about three- fold to nearly $1.66 billion, from $477 million a year earlier. The current period included $455 million from the February sale of rights to the blood-pressure drug Bystolic which had been deferred.See the full content of this document
Extract
Mylan Profits Jump 15 Percent
Net results equaled 45 cents a share, ...
See the full content of this document
Sponsored links
